1 |
GRIA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
2 |
GRIA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
3 |
GRIA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D02696
D02696
|
Talampanel
| 2件: 2 2, 6 |
4 |
GRIA1
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08964
D08964
|
Perampanel
| 3件: 2 2, 6, 144 |
5 |
GRIA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
6 |
GRIA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
7 |
GRIA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D02696
D02696
|
Talampanel
| 2件: 2 2, 6 |
8 |
GRIA2
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08964
D08964
|
Perampanel
| 3件: 2 2, 6, 144 |
9 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
10 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
11 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
12 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07283
D07283
|
Esketamine
| 3件: 2 2, 4, 70 |
13 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
14 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
15 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
16 |
GRIN1
| 8件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D09917
D09917
|
Latrepirdine
| 1件: 8 8 |
17 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
18 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
19 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
20 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D07283
D07283
|
Esketamine
| 3件: 2 2, 4, 70 |
21 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
22 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
23 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
24 |
GRIN2A
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D09917
D09917
|
Latrepirdine
| 1件: 8 8 |
25 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
26 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
27 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
28 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D07283
D07283
|
Esketamine
| 3件: 2 2, 4, 70 |
29 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
30 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
31 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
32 |
GRIN2B
| 9件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Systemic lupus erythematosus | D09917
D09917
|
Latrepirdine
| 1件: 8 8 |
33 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
34 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
35 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
36 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07283
D07283
|
Esketamine
| 3件: 2 2, 4, 70 |
37 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
38 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
39 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
40 |
GRIN2C
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D09917
D09917
|
Latrepirdine
| 1件: 8 8 |
41 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D00775
D00775
|
Riluzole
| 9件: 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
42 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D03742
D03742
|
Dextromethorphan
| 11件: 2 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156 |
43 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07058
D07058
|
Acamprosate
| 2件: 6 6, 206 |
44 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07283
D07283
|
Esketamine
| 3件: 2 2, 4, 70 |
45 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D07441
D07441
|
Amantadine
| 4件: 6 6, 8, 13, 127 |
46 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08098
D08098
|
Ketamine
| 8件: 2 2, 4, 6, 13, 70, 113, 156, 215 |
47 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D08174
D08174
|
Memantine
| 8件: 2 2, 6, 8, 13, 49, 127, 205, 206 |
48 |
GRIN2D
| 6件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Long-term potentiation, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction | D09917
D09917
|
Latrepirdine
| 1件: 8 8 |
49 |
PPP3CA
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
50 |
PPP3CA
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
51 |
PPP3CA
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
52 |
PPP3CA
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
53 |
PPP3CA
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
54 |
PPP3CB
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
55 |
PPP3CB
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
56 |
PPP3CB
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
57 |
PPP3CB
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
58 |
PPP3CB
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
59 |
PPP3CC
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
60 |
PPP3CC
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
61 |
PPP3CC
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
62 |
PPP3CC
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
63 |
PPP3CC
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
64 |
PPP3R1
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
65 |
PPP3R1
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
66 |
PPP3R1
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
67 |
PPP3R1
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
68 |
PPP3R1
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
69 |
PPP3R2
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
70 |
PPP3R2
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
71 |
PPP3R2
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
72 |
PPP3R2
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
73 |
PPP3R2
| 16件: MAPK signaling pathway MAPK signaling pathway, Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Long-term potentiation, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
74 |
PRKCB
| 29件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, NF-kappa B signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Melanogenesis, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, Salivary secretion, Pancreatic secretion, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Morphine addiction, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Non-small cell lung cancer | D11935
D11935
|
Enzastaurin
| 1件: 168 168 |
75 |
MAP2K1
| 41件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
76 |
MAP2K1
| 41件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
77 |
MAP2K1
| 41件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
78 |
MAP2K1
| 41件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
79 |
MAP2K1
| 41件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
80 |
MAP2K2
| 34件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
81 |
MAP2K2
| 34件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
82 |
MAP2K2
| 34件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
83 |
MAP2K2
| 34件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
84 |
MAP2K2
| 34件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
85 |
RAF1
| 36件: MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Melanogenesis, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Melanoma, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
86 |
BRAF
| 20件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
87 |
BRAF
| 20件: MAPK signaling pathway MAPK signaling pathway, Rap1 signaling pathway, mTOR signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Long-term potentiation, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Melanoma, Non-small cell lung cancer | D10064
D10064
|
Dabrafenib
| 1件: 34 34 |
88 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D00349
D00349
|
Isradipine
| 1件: 6 6 |
89 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D00437
D00437
|
Nifedipine
| 2件: 50 50, 81 |
90 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D00537
D00537
|
Topiramate
| 6件: 6 6, 97, 140, 144, 156, 193 |
91 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D01173
D01173
|
Cilnidipine
| 1件: 67 67 |
92 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D01908
D01908
|
Nilvadipine
| 1件: 90 90 |
93 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D02356
D02356
|
Verapamil
| 4件: 58 58, 96, 140, 167 |
94 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D07450
D07450
|
Amlodipine
| 4件: 13 13, 51, 67, 298 |
95 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D07845
D07845
|
Diltiazem
| 3件: 51 51, 58, 86 |
96 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D08270
D08270
|
Nicardipine
| 2件: 70 70, 86 |
97 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D08340
D08340
|
Perhexiline
| 2件: 58 58, 272 |
98 |
CACNA1C
| 11件: MAPK signaling pathway MAPK signaling pathway, Vascular smooth muscle contraction, Long-term potentiation, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Oxytocin signaling pathway, Renin secretion, Type II diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases | D08441
D08441
|
Propiverine
| 1件: 226 226 |